MENS (Jyong Biotech) ROC %: -11.22% (As of Dec. 2025)


MENS Jyong Biotech Ltd MENS
10 GF Score
Price $2.22
! 3 Warning Signs
View Full Analysis

What is Jyong Biotech ROC %?

Jyong Biotech MENS +6.47% 10 ROC % is -11.22% as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Jyong Biotech's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -11.22%.

As of today (2026-07-02), Jyong Biotech's WACC % is 10.51%. Jyong Biotech's ROC % is -9.68% (calculated using TTM income statement data). Jyong Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Jyong Biotech  (NAS:MENS) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Jyong Biotech's WACC % is 10.51%. Jyong Biotech's ROC % is -9.68% (calculated using TTM income statement data). Jyong Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Jyong Biotech ROC % Related Terms


Jyong Biotech ROC % Historical Data

* Premium members only.

The historical data trend for Jyong Biotech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jyong Biotech ROC % Chart

Jyong Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
-20.05 -18.67 -14.79 -11.29 -15.33

Jyong Biotech Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC % Get a 7-Day Free Trial -17.31 -10.37 -12.96 -5.12 -11.22
MENS
10GF Score
Jyong Biotech Ltd MENS
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jyong Biotech ROC % Calculation

Jyong Biotech's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-2.607 * ( 1 - 0% )/( (16.927 + 17.08)/ 2 )
=-2.607/17.0035
=-15.33 %

where

Jyong Biotech's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-3.582 * ( 1 - 0% )/( (46.79 + 17.08)/ 2 )
=-3.582/31.935
=-11.22 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -11.22% mean?
Jyong Biotech (MENS) has a ROC % of -11.22% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Jyong Biotech and its competitors.
Is Jyong Biotech's ROC % too high?
Jyong Biotech's current ROC % is -11.22%. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's ROC % compare to ENLV and CNTB?
Jyong Biotech's ROC % of -11.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Jyong Biotech and its competitors. Jyong Biotech's current ROC % is -11.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current ROC % of -11.22%. The current ROC % is -11.22%. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Jyong Biotech (MENS), the current ROC % is -11.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jyong Biotech Business Description

Address Xintai 5th Road, 23F-3, No. 95, Section 1, Xizhi district, New Taipei, TWN, 221
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score

Get the complete analysis for MENS

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.22
Price